Outlook Therapeutics Future Growth
Future criteria checks 5/6
Outlook Therapeutics is forecast to grow earnings and revenue by 56.4% and 51.2% per annum respectively while EPS is expected to grow by 58.2% per annum.
Key information
56.4%
Earnings growth rate
58.2%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 51.2% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 11 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2027 | 247 | 127 | N/A | N/A | 3 |
| 9/30/2026 | 75 | -10 | N/A | N/A | 3 |
| 9/30/2025 | 9 | -67 | N/A | -69 | 6 |
| 9/30/2024 | N/A | -96 | N/A | -71 | 6 |
| 6/30/2024 | N/A | -94 | -65 | -65 | N/A |
| 3/31/2024 | N/A | -159 | -58 | -58 | N/A |
| 12/31/2023 | N/A | -51 | -47 | -47 | N/A |
| 9/30/2023 | N/A | -59 | -43 | -43 | N/A |
| 6/30/2023 | N/A | -60 | -40 | -40 | N/A |
| 3/31/2023 | N/A | -57 | -48 | -48 | N/A |
| 12/31/2022 | N/A | -70 | -55 | -55 | N/A |
| 9/30/2022 | N/A | -66 | -57 | -57 | N/A |
| 6/30/2022 | N/A | -65 | -55 | -55 | N/A |
| 3/31/2022 | N/A | -60 | -55 | -55 | N/A |
| 12/31/2021 | N/A | -53 | -52 | -52 | N/A |
| 9/30/2021 | N/A | -53 | -54 | -54 | N/A |
| 6/30/2021 | N/A | -50 | -57 | -57 | N/A |
| 3/31/2021 | N/A | -40 | -43 | -43 | N/A |
| 12/31/2020 | N/A | -45 | -38 | -38 | N/A |
| 9/30/2020 | N/A | -49 | -32 | -32 | N/A |
| 6/30/2020 | 6 | -49 | -26 | -26 | N/A |
| 3/31/2020 | 6 | -51 | -30 | -30 | N/A |
| 12/31/2019 | 7 | -45 | -29 | -29 | N/A |
| 9/30/2019 | 8 | -36 | -33 | -32 | N/A |
| 6/30/2019 | 3 | -38 | -36 | -35 | N/A |
| 3/31/2019 | 3 | -43 | -35 | -33 | N/A |
| 12/31/2018 | 3 | -40 | -36 | -34 | N/A |
| 9/30/2018 | 3 | -48 | -36 | -33 | N/A |
| 6/30/2018 | 5 | -43 | -26 | -25 | N/A |
| 3/31/2018 | 5 | -39 | N/A | -22 | N/A |
| 12/31/2017 | 4 | -39 | N/A | -18 | N/A |
| 9/30/2017 | 4 | -40 | N/A | -16 | N/A |
| 6/30/2017 | 1 | -43 | N/A | -26 | N/A |
| 3/31/2017 | 2 | -68 | N/A | -36 | N/A |
| 12/31/2016 | 2 | -64 | N/A | -39 | N/A |
| 9/30/2016 | 3 | -63 | N/A | -45 | N/A |
| 6/30/2016 | 3 | -71 | N/A | -46 | N/A |
| 3/31/2016 | 4 | -53 | N/A | -40 | N/A |
| 12/31/2015 | 3 | -64 | N/A | -36 | N/A |
| 9/30/2015 | 5 | -53 | N/A | -27 | N/A |
| 9/30/2014 | 9 | -21 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 41O is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: 41O is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 41O is expected to become profitable in the next 3 years.
Revenue vs Market: 41O's revenue (51.2% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 41O's revenue (51.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 41O's Return on Equity is forecast to be high in 3 years time